Keywords: Research productivity, NMEs, In-licenisng, Clinical dropouts, Thomson Reuters

Clinical trial drug dropouts reach unsustainable levels, says Thomson Reuters repo

Article | 28 June 2011

The pharmaceutical industry spent less on drug R&D last year than at any time in the last three ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in